ArticleESMO open2026

Compartment-specific immune and tumor markers associated with clinical outcomes in patients with and without sarcomatoid/rhabdoid renal cell carcinoma treated with ipilimumab and nivolumab.

N Savion-Gaiger et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.